Please login to the form below

Not currently logged in

UK pharma's contribution to NHS hits £1bn mark

ABPI says local access to new treatments still not universal despite drug rebates

New figures from the UK pharma industry claim the sector has contributed more than £1bn to the NHS as part of the Pharmaceutical Payment Regulation Scheme (PPRS).

The PPRS controls the price of branded medicines in the NHS and results from a negotiation between the UK government and the Association of the British Pharmaceutical Industry (ABPI), as the representative body for those companies supplying the NHS with medicines.

Since 2013, UK pharma firms have been given strict limits and must pay the NHS back any money they make over the agreed limit in the form of a rebate. The idea is to help make new drug treatments more affordable for the NHS and give UK patients the same level of access to new medicines as other EU countries.

All told, the ABPI expects the industry's contribution over the current five-year PPRS period to reach £3bn, helping to ensure "more NHS patients can benefit from NICE approved medicines", according to ABPI executive director Richard Torbett.

Towards the end of last year, the ABPI agreed a new arrangement with the UK government in which it brought forward around £200m of the estimated payments for 2017/18 in to the 2015/16 period. The aim was to assist the NHS' Five Year Forward View initiative.

Access barriers still in place
Despite contributions from industry, new medicines approved as clinically and cost effective by NICE are not always being adopted and used by the NHS locally, says the ABPI.

The overall NHS spend on branded medicines covered under the PPRS scheme is essentially flat - coming in at £2.14bn in 2014/15 and £2.15nn in 2015/16, it adds.

"To ensure we are making the most of this opportunity, we need to sit down with colleagues in the Department of Health and the NHS and establish how to remove barriers which are currently preventing the NHS from effectively rolling out the use of these new treatments" says Torbett.

"We hope that the government's independent Accelerated Access Review … will provide an opportunity to address some of these issues."

The AAR was announced by Minister for Life Sciences George Freeman in November 2014 after it became apparent that plans to replace the PPRS with a value-based pricing model - along with reforms to NICE procedures - were unlikely to solve issues surrounding new medicines access in the NHS. At last count the review was scheduled for publication in April of this year.

Article by
Phil Taylor

10th March 2016

From: Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...